Summary
Flurazepam Hydrochloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Insomnia / Sleep Disorders would be drug repurposing rather than first-in-human development. This does not mean it is approved for Insomnia / Sleep Disorders. No registered clinical trial in this database tests Flurazepam Hydrochloride specifically in Insomnia / Sleep Disorders. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 5 publications for this pair: 5 clinical trial publications. Publication years run from 1973 to 1982. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Insomnia ranks 317 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Acute insomnia (<3 months): 50-60% resolve spontaneously; chronic insomnia: only 20-25% spontaneous remission at 1 year; persistent insomnia in 50-75% without treatment.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 30.0 (trials 0.0, literature 10.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 5 (5 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Flurazepam Hydrochloride to Insomnia / Sleep Disorders in the current OSMF trial extract.
Published literature
- Clinical trial publication Double-blind evaluation of temazepam, flurazepam, and placebo in geriatric insomniacsFillingim JM · Clinical therapeutics · 1982 · PMID 6121625
- Clinical trial publication Insomnia in the elderly: treatment with flurazepam hydrochlorideFrost JD Jr, DeLucchi MR · Journal of the American Geriatrics Society · 1979 · PMID 229146
- Clinical trial publication Comparison of the hypnotic activity of triazolam, flurazepam hydrochloride, and placeboSunshine A · Clinical pharmacology and therapeutics · 1975 · PMID 236108
- Clinical trial publication A double-blind evaluation of a new hypnotic--flurazepam hydrochlorideSwanson DA · South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde · 1973 · PMID 4578725
- Clinical trial publication Controlled evaluation of flurazepam hydrochloride, a new nonbarbiturate hypnoticMeyer JA, Kurland KZ · Military medicine · 1973 · PMID 4200136
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Flurazepam Hydrochloride approved for Insomnia / Sleep Disorders?
Flurazepam Hydrochloride has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Insomnia / Sleep Disorders would be drug repurposing rather than first-in-human development. This does not mean it is approved for Insomnia / Sleep Disorders. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Flurazepam Hydrochloride in clinical trials for Insomnia / Sleep Disorders?
No registered clinical trial in this database tests Flurazepam Hydrochloride specifically in Insomnia / Sleep Disorders. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Flurazepam Hydrochloride in Insomnia / Sleep Disorders?
The record for Flurazepam Hydrochloride in Insomnia / Sleep Disorders rests on 5 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.